介绍
本页面提供了有关 Vivo Ventures Vii, Llc 已知的内部交易历史的全面分析。内部人士包括公司的高管、董事或重要投资者。一般而言,基于内幕、非公开信息进行交易是非法的。这并不意味着他们在自己的公司进行任何交易都是非法的。但是,他们必须通过Form 4向美国证券交易委员会(SEC)报告所有交易。尽管存在这些限制,学术研究表明,整体而言,内部人士在自己公司中的投资表现往往优于市场。
平均交易盈利能力
“平均交易盈利能力”衡量了内部人士在过去三年中所有非计划性的公开市场买入交易的平均回报率。计算过程包括检查每笔交易,排除了作为10b5-1交易计划的一部分的交易。然后,对每笔交易在3、6和12个月的表现进行平均,以生成该笔交易最终的表现指标。然后,将所有交易的表现指标进行平均,计算出内部人士的总体平均表现指标。列表仅包含在过去两年中进行过至少三笔交易的内部人士。
如果内部人士的交易盈利能力显示为"N/A",则可能是因为该内部人士在过去三年内没有进行任何公开市场买入交易,或者他们进行的交易距离现在时间太近,无法计算出可靠的表现指标。
更新频率:每日
报告内部持仓的公司
美国证券交易委员会(SEC)文件显示Vivo Ventures Vii, Llc已报告在以下公司拥有持仓或进行了交易:
证券 | 职位 | 最新报告的持仓 |
---|---|---|
US:SRRA / Sierra Oncology Inc | Director, 10% Owner | 0 |
10% Owner | 788,873 | |
US:CDXS / Codexis, Inc. | 10% Owner | 90,330 |
US:ACRS / Aclaris Therapeutics, Inc. | 10% Owner | 60,972 |
US:MEIP / MEI Pharma, Inc. | 10% Owner | 3,163,105 |
如何解读这些图表
以下图表显示了在Vivo Ventures Vii, Llc进行的每笔公开市场非计划交易后证券的股价表现。非计划交易是指没有作为10b5-1交易计划的一部分而进行的交易。股价表现以累积百分比变化的方式绘制。例如,如果一笔内部人士交易是在2019年1月1日进行的,该图表将显示该证券的每日百分比变化直至当前日期。如果在此期间股价从10美元涨至15美元,则股价的累积百分比变化将为50%。从10美元涨至20美元的价格变化将为100%,而从10美元跌至5美元的价格变化将为-50%。
最终,我们将评估内部人士的交易与股价的超额回报(正向或负向)之间的相关性,以判断内部人士是否在交易中利用内部信息获利。如果内部人士有这样的行为,我们预期看到(a)买入后的正回报,或者(b)卖出后的负回报。对于情况(a),买入图表将显示一系列向上倾斜的曲线,表示每次买入后都有正回报。对于情况(b),卖出图表将显示一系列向下倾斜的曲线,表示每次卖出后都有负回报。
然而,仅凭这一点还不足以得出结论。例如,如果公司的股价在多年内呈现非周期性上升,我们会预期所有买入后的图表都呈现向上倾斜。同样地,多年来呈现非周期性下降的股价会导致卖出后的图表也呈现向下倾斜。这两种情况的图表都不能表示内部人士在进行内幕交易。
最有力的指标是在公司股价呈极度循环波动的情况下,“买入”图表显示正向信号,而“卖出”图表显示负向趋势。这种情况强烈暗示内部人士可能根据内幕信息精确地计时进行交易,以获得财务优势。
ACRS / Aclaris Therapeutics, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
ACRS / Aclaris Therapeutics, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
CDXS / Codexis, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
CDXS / Codexis, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
MEIP / MEI Pharma, Inc.内部人士买入 - 短期收益分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士买入的盈利情况。这种分析有助于了解内部人士是否持续产生异常的回报,以及是否值得跟踪。该分析基于每笔交易后一年的情况,结果仅为理论值。
MEIP / MEI Pharma, Inc.内部人士卖出 - 短期亏损分析
在这一部分,我们分析了在 ACRS / Aclaris Therapeutics, Inc. 中进行的每笔非计划的公开市场内部人士卖出所达成的短期亏损规避。如果存在持续的亏损规避模式,可能表明未来的内部人士卖出交易预示着价格的下跌。该分析基于每笔交易后一年的情况,
以下表格显示了最近的自动交易计划之外的公开市场买入。
经调整价格 已按拆股调整。经调整股数 已按拆股调整。
内幕交易历史
该表格显示了由 Vivo Ventures Vii, Llc 进行的所有内幕交易的完整列表,这些交易已向美国证券交易委员会(SEC)披露。
备案日期 | 交易日期 | 表格 | 股票代码 | 证券 | 代码 | 股数 | 剩余股数 | % 变化 |
每股 股价 |
交易 金额 |
剩余 金额 |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -431,947 | 0 | -100.00 | 55.00 | -23,757,085 | ||
2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -2,735,853 | 0 | -100.00 | 55.00 | -150,471,915 | ||
2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -161,712 | 0 | -100.00 | 55.00 | -8,894,160 | ||
2022-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
P - Purchase | 800,000 | 2,735,853 | 41.33 | 27.00 | 21,600,000 | 73,868,031 | |
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrant (Right to Purchase ) |
X - Other | -324,740 | 0 | -100.00 | 13.20 | -4,286,568 | ||
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrant (Right to Purchase ) |
X - Other | -1,455,384 | 0 | -100.00 | 13.20 | -19,211,069 | ||
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrant (Right to Purchase ) |
X - Other | -75,749 | 0 | -100.00 | 13.20 | -999,887 | ||
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 107,164 | 431,947 | 33.00 | 13.20 | 1,414,565 | 5,701,700 | |
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 480,277 | 1,935,853 | 33.00 | 13.20 | 6,339,656 | 25,553,260 | |
2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 24,996 | 161,712 | 18.28 | 13.20 | 329,947 | 2,134,598 | |
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -4,287 | 0 | -100.00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -19,213 | 0 | -100.00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -1,000 | 0 | -100.00 | ||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 324,783 | 324,783 | |||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 1,455,576 | 1,455,576 | |||||
2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 75,759 | 136,715 | 124.28 | ||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2019-12-02 | 3 | SRRA |
Sierra Oncology, Inc.
Common Stock |
4,876,540 | ||||||||
2018-08-31 |
|
4 | AXP |
AIRXPANDERS INC
Common Stock |
P - Purchase | 429,631 | 788,873 | 119.59 | 0.17 | 71,834 | 131,900 | |
2018-08-31 |
|
4 | AXP |
AIRXPANDERS INC
Common Stock |
P - Purchase | 19,712,492 | 36,195,409 | 119.59 | 0.17 | 3,295,929 | 6,051,872 | |
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
33,325,076 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
17,201,401 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
33,325,076 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
17,201,401 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
33,325,076 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
17,201,401 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
33,325,076 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
17,201,401 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
33,325,076 | ||||||||
2018-08-31 | 3 | AXP |
AIRXPANDERS INC
Common Stock |
17,201,401 | ||||||||
2017-09-18 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -22,610 | 90,330 | -20.02 | 5.78 | -130,573 | 521,656 | |
2017-09-18 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -1,037,390 | 4,144,495 | -20.02 | 5.78 | -5,990,927 | 23,934,459 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -2,666 | 60,972 | -4.19 | 31.20 | -83,179 | 1,902,326 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -122,334 | 2,797,597 | -4.19 | 31.20 | -3,816,821 | 87,285,026 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -2,133 | 63,638 | -3.24 | 30.98 | -66,080 | 1,971,505 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -97,867 | 2,919,931 | -3.24 | 30.98 | -3,031,920 | 90,459,462 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -4,266 | 65,771 | -6.09 | 30.50 | -130,113 | 2,006,016 | |
2017-03-02 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -195,734 | 3,017,798 | -6.09 | 30.50 | -5,969,887 | 92,042,839 | |
2016-11-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -9,598 | 70,037 | -12.05 | 22.72 | -218,067 | 1,591,241 | |
2016-11-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -440,402 | 3,213,532 | -12.05 | 22.72 | -10,005,933 | 73,011,447 | |
2016-11-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -9,765 | 79,635 | -10.92 | 27.30 | -266,584 | 2,174,036 | |
2016-11-18 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
S - Sale | -448,063 | 3,653,934 | -10.92 | 23.25 | -10,417,465 | 84,953,966 | |
2016-09-12 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -2,381 | 112,940 | -2.06 | 4.25 | -10,126 | 480,323 | |
2016-09-12 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -109,219 | 5,181,885 | -2.06 | 4.25 | -464,497 | 22,038,039 | |
2016-08-17 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -787 | 115,321 | -0.68 | 4.21 | -3,311 | 485,179 | |
2016-08-17 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -36,107 | 5,291,104 | -0.68 | 4.21 | -151,909 | 22,260,733 | |
2016-08-17 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -1,066 | 116,108 | -0.91 | 4.27 | -4,556 | 496,246 | |
2016-08-17 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -48,934 | 5,327,211 | -0.91 | 4.27 | -209,144 | 22,768,500 | |
2016-08-05 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -1,066 | 117,174 | -0.90 | 4.17 | -4,444 | 488,428 | |
2016-08-05 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -48,934 | 5,376,145 | -0.90 | 4.17 | -203,976 | 22,409,923 | |
2016-08-05 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -640 | 118,240 | -0.54 | 4.30 | -2,751 | 508,231 | |
2016-08-05 |
|
4 | CDXS |
CODEXIS INC
Common Stock |
S - Sale | -29,360 | 5,425,079 | -0.54 | 4.30 | -126,198 | 23,318,617 | |
2015-11-09 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -157,352 | 3,163,105 | -4.74 | 1.75 | -275,366 | 5,535,434 | |
2015-11-09 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -7,560 | 3,320,457 | -0.23 | 1.85 | -13,986 | 6,142,845 | |
2015-11-09 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -225,660 | 3,328,017 | -6.35 | 1.91 | -431,011 | 6,356,512 | |
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -29,337 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1,346,068 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -38,782 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1,779,400 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -184,557 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -8,467,943 | 0 | -100.00 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
P - Purchase | 9,695 | 89,400 | 12.16 | 11.00 | 106,645 | 983,400 | |
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
C - Conversion | 73,238 | 79,705 | 1,132.49 | ||||
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
P - Purchase | 444,850 | 4,101,997 | 12.16 | 11.00 | 4,893,350 | 45,121,967 | |
2015-10-13 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
C - Conversion | 3,360,408 | 3,657,147 | 1,132.45 | ||||
2015-10-09 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
P - Purchase | 285 | 6,467 | 4.61 | 11.00 | 3,135 | 71,137 | |
2015-10-09 |
|
4 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
P - Purchase | 13,067 | 296,739 | 4.61 | 11.00 | 143,737 | 3,264,129 | |
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
573,526 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
296,036 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
573,526 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
296,036 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
573,526 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
296,036 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
573,526 | ||||||||
2015-10-06 | 3 | ACRS |
Aclaris Therapeutics, Inc.
Common Stock |
296,036 | ||||||||
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Series D Preferred Stock |
C - Conversion | -44,991 | 0 | -100.00 | ||||
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Series D Preferred Stock |
C - Conversion | -2,064,308 | 0 | -100.00 | ||||
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
P - Purchase | 4,693 | 2,438,270 | 0.19 | 17.00 | 79,781 | 41,450,590 | |
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
P - Purchase | 215,307 | 2,433,577 | 9.71 | 17.00 | 3,660,219 | 41,370,809 | |
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
J - Other | 2,324 | 2,218,270 | 0.10 | 5.22 | 12,120 | 11,568,278 | |
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
J - Other | 106,647 | 2,215,946 | 5.06 | 5.22 | 556,164 | 11,556,158 | |
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
C - Conversion | 44,991 | 2,109,299 | 2.18 | ||||
2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
C - Conversion | 2,064,308 | 2,064,308 | |||||
2015-03-26 |
|
4 | MEIP |
MEI Pharma, Inc.
Warrant to Purchase Common Stock |
O - Other | 420,000 | 0 | -100.00 | ||||
2015-03-26 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
O - Other | 455,174 | 3,553,677 | 14.69 | 3.12 | 1,420,143 | 11,087,472 | |
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
11,027,758 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
5,692,199 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
11,027,758 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
5,692,199 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
11,027,758 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
5,692,199 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
11,027,758 | ||||||||
2015-03-24 | 3 | CDXS |
CODEXIS INC
Common Stock |
5,692,199 | ||||||||
2013-10-29 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -756 | 3,098,503 | -0.02 | 8.27 | -6,252 | 25,624,620 | |
2013-10-29 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -38,953 | 3,099,259 | -1.24 | 8.30 | -323,435 | 25,733,767 | |
2013-10-29 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -259,900 | 3,138,212 | -7.65 | 8.20 | -2,131,180 | 25,733,338 | |
2013-10-03 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -486,107 | 3,398,112 | -12.51 | 10.00 | -4,861,507 | 33,984,178 | |
2013-10-03 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -95,539 | 3,884,219 | -2.40 | 11.00 | -1,050,671 | 42,715,922 | |
2013-07-02 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -7,337 | 3,979,758 | -0.18 | 7.58 | -55,598 | 30,157,412 | |
2013-06-13 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -236,273 | 3,987,095 | -5.59 | 7.80 | -1,842,929 | 31,099,341 | |
2013-05-20 |
|
4 | MEIP |
MEI Pharma, Inc.
Common Stock |
S - Sale | -17,428 | 4,223,368 | -0.41 | 9.07 | -157,994 | 38,286,943 | |
2012-12-21 | 3 | MEIP |
MEI Pharma, Inc.
Common Stock |
4,660,796 |